DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE ...
March 15 2021 - 8:30AM
Daxor Corporation (NYSE MKT: DXR), the global leader in blood
volume measurement technology, announces today that it has been
awarded a phase-two contract from the United States Air Force
(USAF) to implement a novel fluorescent tracer and optical sensing
technology into a next-generation point-of-care blood volume
analyzer. This is the fourth contract award Daxor has received from
the Department of Defense (DoD) in the past two years, totaling
more than $2 million dollars for the manufacture of advanced blood
volume analyzers for military and civilian applications.
“We are pleased to share with the public our
innovative fluorescing tracer and optical blood volume diagnostic
program which has been awarded a $750,000 contract from the USAF.
This contract will further enhance the capabilities for our
state-of-the-art technology making precise blood volume measurement
both easier and quicker in both combat casualty care and civilian
settings,” said Michael Feldschuh, President and CEO of Daxor.
“Daxor’s BVA-100 Blood Volume Analysis (BVA) technology transforms
the existing standard of care by ensuring resuscitation and
transfusion treatment decisions are based on precise measurement of
blood volume for better patient survival and outcomes. Our
next-generation system promises to be even faster, easier, and
usable in a broader range of care settings from the battlefield to
the outpatient clinic to bedside in the ICU.”
“This represents a significant milestone for our
technology. The invention of a novel fluorescent tracer optimized
for blood volume measurement, for which we have several patents
pending, will expand use of our test into more clinical settings
for more indications,” said Jonathan Feldschuh, Chief Scientific
Officer of Daxor. “This tracer will support our next generation
optical analyzer allowing for point-of-care measurement expanding
our product offerings to include both nuclear and fluorescing-based
testing options. We are excited to accelerate our development under
this contract with the DoD.”
The phase-two funding was made possible through
the highly competitive SBIR program of AFWERX, the USAF team of
innovators who encourage and facilitate connections across
industry, academia, and the military to create transformative
opportunities for the development of rapid and affordable
commercial and military technologies and solutions that meet
critical healthcare needs.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation (organized as an investment company with
fully-owned innovative medical instrumentation and biotechnology
operations). We developed and market the BVA-100® (Blood Volume
Analyzer), the first diagnostic blood test cleared by the FDA to
provide safe, accurate, objective quantification of blood volume
status and composition compared to patient-specific norms. The BVA
technology enhances hospital performance metrics in a broad range
of surgical and medical conditions, including heart failure and
critical care, by informing treatment strategies, resulting in
significantly improved multiple measures of patient outcomes.
Daxor's mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2023 to Aug 2024